Eli Lilly (LLY) Share-based Compensation (2016 - 2025)
Historic Share-based Compensation for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $151.1 million.
- Eli Lilly's Share-based Compensation rose 1343.84% to $151.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $631.8 million, marking a year-over-year increase of 126.62%. This contributed to the annual value of $645.6 million for FY2024, which is 272.08% up from last year.
- Latest data reveals that Eli Lilly reported Share-based Compensation of $151.1 million as of Q3 2025, which was up 1343.84% from $185.1 million recorded in Q2 2025.
- In the past 5 years, Eli Lilly's Share-based Compensation registered a high of $215.6 million during Q3 2023, and its lowest value of $75.3 million during Q4 2021.
- Over the past 5 years, Eli Lilly's median Share-based Compensation value was $131.2 million (recorded in 2023), while the average stood at $130.4 million.
- Per our database at Business Quant, Eli Lilly's Share-based Compensation surged by 15334.9% in 2023 and then plummeted by 3821.89% in 2024.
- Over the past 5 years, Eli Lilly's Share-based Compensation (Quarter) stood at $75.3 million in 2021, then increased by 23.37% to $92.9 million in 2022, then rose by 29.39% to $120.2 million in 2023, then increased by 18.05% to $141.9 million in 2024, then grew by 6.48% to $151.1 million in 2025.
- Its Share-based Compensation was $151.1 million in Q3 2025, compared to $185.1 million in Q2 2025 and $153.7 million in Q1 2025.